Supplement interactions
Documented interactions of supplements with medicines, with each other and with food, in tables you can filter. Each row links to the NIH, FDA or peer-reviewed source it was taken from.
Mueller et al., Eur J Clin Pharmacol 2006; NCCIH, Goldenseal (February 2025); 21 U.S.C. 379aa-1.
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Do not start, stop or change the timing of a medicine because of this page; tell your doctor or pharmacist about every supplement you take. An interaction missing here may still exist.
Related: Supplements A–Z · How to judge a supplement · ADME, PK and PBPK · Combination science
Filter the interaction tables
A pair missing from these tables is not a pair known to be safe. The tables hold 79 documented interactions from the sources cited; many combinations have never been studied. Ask a pharmacist or physician about any supplement taken with a medicine.
Where interactions happen
An interaction is a change in the effect of a medicine or nutrient caused by something taken with it. The rows below act in four places. In the gut, minerals bind drugs or change absorption. In the gut wall and liver, enzymes and transporters clear drugs. Other pairs act on the same body system, or in the kidney.
A row names the mechanism only when its source states one. “Mechanism not stated by the source” means the interaction is documented, not explained.
Herbs with medicines
St. John's wort has the longest documented list. NCCIH says it “can weaken the effects of many medicines” and calls it a potent inducer of cytochrome P450 enzymes and intestinal P-glycoprotein; how strongly it induces depends on the product's hyperforin content. Goldenseal works the other way at CYP3A and raises exposure.
For ginkgo and garlic the documented concern is bleeding with anticoagulants. The pharmacokinetic studies are discussed in ADME, PK and PBPK.
| Supplement | With | What happens | What the source advises or adds | Source |
|---|---|---|---|---|
| St. John's wort | Some antidepressants, including amitriptyline and bupropion | Can weaken the effect of the medicine.Metabolism or transport | NCCIH St. John's wort NCCIH herb–drug digest | |
| St. John's wort | Birth control pills | Can weaken the effect of the medicine.Metabolism or transport | NCCIH St. John's wort NCCIH herb–drug digest | |
| St. John's wort | Cyclosporine (prevents rejection of transplanted organs) | Can weaken the effect; NCCIH calls the interaction clinically significant.Metabolism or transport | NCCIH St. John's wort NCCIH herb–drug digest | |
| St. John's wort | Seizure medicines phenytoin and carbamazepine | Can weaken the effect of the medicine.Metabolism or transport | NCCIH St. John's wort | |
| St. John's wort | Heart medicines digoxin and ivabradine | Can weaken the effect of the medicine.Metabolism or transport | NCCIH St. John's wort NCCIH herb–drug digest | |
| St. John's wort | HIV medicines indinavir and nevirapine | Can weaken the effect of the medicine.Metabolism or transport | NCCIH St. John's wort NCCIH herb–drug digest | |
| St. John's wort | Cancer medicines irinotecan, imatinib and docetaxel | Can weaken the effect of the medicine.Metabolism or transport | NCCIH St. John's wort | |
| St. John's wort | Warfarin (anticoagulant) | Can weaken the effect of the medicine.Metabolism or transport | NCCIH St. John's wort NCCIH herb–drug digest | |
| St. John's wort | Certain statins, including simvastatin | Can weaken the effect of the medicine.Metabolism or transport | NCCIH St. John's wort | |
| St. John's wort | Antidepressants or other drugs that affect serotonin | May increase serotonin-related side effects, which can be serious.Same body system | NCCIH St. John's wort NCCIH herb–drug digest | |
| St. John's wort | Midazolam (test drug for the CYP3A enzyme) | 14 days in 42 healthy men: oral midazolam AUC0–12 h fell 79.4%, 47.9% and 21.1% with products giving 41, 12 and 0.13 mg/day hyperforin.Metabolism or transport | FDA lists St. John's wort as a strong CYP3A inducer and notes that its effect “varies widely and is preparation dependent.” | Mueller 2006 FDA interaction table |
| Goldenseal | Metformin (diabetes medicine) | Metformin levels fell about 25% in healthy adults given goldenseal extract.Mechanism not stated by the source | NCCIH: enough to potentially hinder glucose control in people with type 2 diabetes taking metformin. A 2025 crossover study in adults with type 2 diabetes found no clinically meaningful interaction overall (metformin AUC ratio 0.93), with about a 20% fall at low metformin doses (Nguyen 2025, Clin Transl Sci 18:e70120). | NCCIH goldenseal NCCIH herb–drug digest |
| Goldenseal | Medicines processed by the enzymes CYP2D6 and CYP3A4 | Goldenseal has been shown to inhibit both enzymes.Metabolism or transport | NCCIH herb–drug digest | |
| Goldenseal | Midazolam (test drug for the CYP3A enzyme) | Oral midazolam AUC ratio 1.43 (90% CI 1.35–1.53); in a second study AUC and Cmax rose 40–60%, mainly by intestinal CYP3A inhibition.Metabolism or transport | Intravenous midazolam AUC ratio 0.97: no systemic effect. | Nguyen 2021 Nguyen 2023 |
| Ginkgo | Warfarin (anticoagulant) | Associated with an increased risk of major bleeding events compared with warfarin alone.Mechanism not stated by the source | NCCIH herb–drug digest NCCIH ginkgo | |
| Ginkgo | Efavirenz (HIV medicine) | Using ginkgo preparations with efavirenz is not recommended.Mechanism not stated by the source | NCCIH herb–drug digest | |
| Garlic | Anticoagulants or aspirin | Garlic supplements may increase the risk of bleeding.Mechanism not stated by the source | Tell your health care providers, especially before surgery. | NCCIH garlic |
| Green tea | Nadolol (beta-blocker) | Green tea at high doses reduced blood levels, and therefore the effectiveness, of nadolol.Mechanism not stated by the source | NCCIH herb–drug digest | |
| Green tea extract | Atorvastatin (statin) | Can reduce blood levels of atorvastatin.Mechanism not stated by the source | NCCIH herb–drug digest | |
| Chamomile | Oral contraceptives | Might decrease the effects of oral contraceptives.Mechanism not stated by the source | NCCIH herb–drug digest | |
| Chamomile | Warfarin and some drugs metabolized by the liver | Interactions have been reported.Mechanism not stated by the source | NCCIH notes theoretical reasons to suspect interactions with other drugs, such as sedatives. | NCCIH herb–drug digest |
| Asian ginseng | Warfarin (anticoagulant) | Studies have had mixed results.Mechanism not stated by the source | Interactions with calcium channel blockers, other blood pressure medicines, statins and some antidepressants are uncertain. | NCCIH herb–drug digest |
| Cranberry | Warfarin (anticoagulant) | Evidence on whether cranberry interacts with warfarin is conflicting.Mechanism not stated by the source | NCCIH herb–drug digest | |
| Cat's claw | Anticoagulant and antiplatelet drugs, blood pressure drugs, calcium channel blockers, CYP3A4 substrates, immunosuppressants | May interact; NCCIH describes these interactions as theoretical.Mechanism not stated by the source | NCCIH herb–drug digest | |
| Licorice root | Corticosteroids | Interactions have been reported.Mechanism not stated by the source | Glycyrrhizin in licorice can cause irregular heartbeat and cardiac arrest, especially in large amounts or long-term use. | NCCIH licorice root |
No rows in this table match the filter.
Vitamins and minerals with medicines
Minerals act mostly in the gut: calcium, magnesium, iron and zinc lower the absorption of some antibiotics, levothyroxine, bisphosphonates, dolutegravir and levodopa. Common medicines also lower nutrients: proton pump inhibitors (vitamin B12, iron, magnesium), metformin (B12), orlistat (vitamins A, D and K) and diuretics (magnesium, potassium, zinc).
| Supplement | With | What happens | What the source advises or adds | Source |
|---|---|---|---|---|
| Vitamin K | Warfarin and similar anticoagulants (phenprocoumon, acenocoumarol, tioclomarol) | A serious and potentially dangerous interaction: these drugs work by antagonizing vitamin K.Same body system | Keep vitamin K intake consistent; sudden changes can strengthen or weaken the anticoagulant effect. | ODS vitamin K |
| Vitamin K | Antibiotics, especially cephalosporins | May lower vitamin K status by killing vitamin K-producing gut bacteria.Nutrient status | Supplements are usually unnecessary unless use lasts several weeks or more and intake is poor. | ODS vitamin K |
| Vitamin K | Bile acid sequestrants (cholestyramine, colestipol) | Can reduce absorption of vitamin K and other fat-soluble vitamins; clinical significance unclear.Absorption | ODS vitamin K | |
| Vitamin K | Orlistat | Reduces absorption of fat-soluble vitamins; with warfarin it may significantly increase prothrombin time.Absorption | ODS vitamin K | |
| Vitamin A | Orlistat | Can decrease absorption of vitamin A, other fat-soluble vitamins and beta-carotene.Absorption | ODS vitamin A | |
| Vitamin A | Retinoids (acitretin, bexarotene) | Can increase the risk of hypervitaminosis A when taken with vitamin A supplements.Same body system | ODS vitamin A | |
| Vitamin D | Orlistat | Can reduce absorption of vitamin D from food and supplements, lowering 25(OH)D levels.Absorption | ODS vitamin D | |
| Vitamin D | Statins (atorvastatin, lovastatin, simvastatin) | Statins may reduce vitamin D synthesis; high vitamin D intakes might reduce the potency of these statins, which appear to compete for the same metabolizing enzyme.Metabolism or transport | ODS vitamin D | |
| Vitamin E | Anticoagulant and antiplatelet medicines | Vitamin E can inhibit platelet aggregation and antagonize vitamin K-dependent clotting factors; large doses can increase bleeding risk.Same body system | ODS vitamin E | |
| Vitamin E and other antioxidants | Simvastatin with niacin | Antioxidant ingredients blunted the rise in HDL cholesterol.Mechanism not stated by the source | ODS vitamin E | |
| Vitamin E, vitamin C and other antioxidants | Cancer chemotherapy or radiotherapy | Might reduce the effectiveness of these therapies; oncologists generally advise against antioxidant supplements during treatment.Mechanism not stated by the source | Consult the oncologist before taking vitamin C or other antioxidant supplements. | ODS vitamin E ODS vitamin C |
| Vitamin C | Statins | Health care providers should monitor lipid levels in people taking statins and antioxidant supplements.Mechanism not stated by the source | ODS vitamin C | |
| Vitamin B6 | Cycloserine (tuberculosis medicine) | Increases urinary excretion of pyridoxine, which may worsen the drug's seizure and neurotoxicity risks.Excretion | Pyridoxine supplements can help prevent these effects. | ODS vitamin B6 |
| Vitamin B6 | Antiepileptics (valproic acid, carbamazepine, phenytoin) | These drugs speed vitamin B6 breakdown and lower plasma PLP; pyridoxine 200 mg/day for 12–120 days can reduce serum phenytoin and phenobarbital.Metabolism or transport | ODS vitamin B6 | |
| Vitamin B6 | Theophylline | Patients treated with theophylline often have low plasma PLP concentrations.Nutrient status | ODS vitamin B6 | |
| Folate (folic acid) | Methotrexate | People taking methotrexate for cancer should consult their oncologist first; folate might reduce gastrointestinal side effects of low-dose methotrexate.Mechanism not stated by the source | ODS folate | |
| Folate (folic acid) | Antiepileptic medicines | These medicines can reduce serum folate; folate supplements might reduce serum levels of the medicines.Nutrient status | ODS folate | |
| Folate (folic acid) | Sulfasalazine | Inhibits intestinal absorption of folate and can cause folate deficiency.Absorption | ODS folate | |
| Vitamin B12 | Proton pump inhibitors (omeprazole, lansoprazole) and H2 blockers (cimetidine, ranitidine) | Can interfere with B12 absorption from food by slowing the release of gastric acid, and can lead to deficiency.Absorption | ODS vitamin B12 | |
| Vitamin B12 | Metformin | Might reduce B12 absorption and significantly reduce serum B12 concentrations.Absorption | ODS vitamin B12 | |
| Calcium | Dolutegravir (HIV medicine) | Can substantially lower dolutegravir blood levels, apparently through chelation.Absorption | Labels advise dolutegravir 2 hours before or 6 hours after calcium supplements. | ODS calcium |
| Calcium | Levothyroxine | Calcium carbonate can impair levothyroxine absorption.Absorption | The label advises against levothyroxine within 4 hours of the supplement. | ODS calcium |
| Calcium | Lithium | Long-term lithium can cause hypercalcemia; calcium supplements may raise that risk.Same body system | ODS calcium | |
| Calcium | Quinolone antibiotics (ciprofloxacin, gemifloxacin, moxifloxacin) | Calcium can reduce absorption of these antibiotics.Absorption | Taking the antibiotic 2 hours before or 2 hours after calcium prevents this effect. | ODS calcium |
| Magnesium | Oral bisphosphonates (alendronate) | Magnesium-rich supplements or medicines can decrease bisphosphonate absorption.Absorption | Separate them by at least 2 hours. | ODS magnesium |
| Magnesium | Tetracyclines (demeclocycline, doxycycline) and quinolones (ciprofloxacin, levofloxacin) | Magnesium can form insoluble complexes with these antibiotics.Absorption | Take the antibiotic at least 2 hours before or 4–6 hours after magnesium. | ODS magnesium |
| Magnesium | Loop diuretics (furosemide, bumetanide, ethacrynic acid) and thiazide diuretics (hydrochlorothiazide) | Chronic use can increase urinary magnesium loss and lead to depletion; potassium-sparing diuretics (amiloride, spironolactone) reduce magnesium excretion.Excretion | ODS magnesium | |
| Magnesium | Proton pump inhibitors (esomeprazole, lansoprazole) | Can cause hypomagnesemia when taken for prolonged periods (typically more than a year); in 25% of cases FDA reviewed, supplements did not raise magnesium and the PPI had to be stopped.Nutrient status | ODS magnesium | |
| Iron | Levodopa | Iron supplements reduce levodopa absorption in healthy people, possibly through chelation.Absorption | ODS iron | |
| Iron | Levothyroxine | Can significantly reduce levothyroxine efficacy in some patients.Absorption | Some labels advise against levothyroxine within 4 hours of iron supplements. | ODS iron |
| Iron | Proton pump inhibitors | Lower stomach acidity can reduce nonheme iron absorption; patients with iron deficiency can respond poorly to iron supplements.Absorption | ODS iron | |
| Zinc | Quinolone and tetracycline antibiotics | Zinc may interact with these antibiotics.Absorption | Taking the antibiotic at least 2 hours before or 4–6 hours after zinc minimizes the interaction. | ODS zinc |
| Zinc | Penicillamine | Zinc may interact with penicillamine.Absorption | Take zinc and penicillamine at least 1 hour apart. | ODS zinc |
| Zinc | Some diuretics | Can decrease serum zinc by increasing zinc excretion in urine.Excretion | ODS zinc | |
| Potassium | ACE inhibitors and angiotensin receptor blockers | Reduce urinary potassium excretion, which can lead to hyperkalemia.Excretion | Experts recommend monitoring potassium status. | ODS potassium |
| Potassium | Potassium-sparing diuretics | Reduce urinary potassium excretion and can cause hyperkalemia.Excretion | Experts recommend monitoring potassium status. | ODS potassium |
| Potassium | Loop and thiazide diuretics | Increase urinary potassium excretion and can lead to hypokalemia.Excretion | Experts recommend monitoring and supplementation if warranted. | ODS potassium |
| Omega-3 (fish oil) | Warfarin | Fish oil might prolong clotting time (higher INR); most research finds 3–6 g/day does not significantly affect anticoagulant status.Same body system | Labels of FDA-approved omega-3 drugs advise periodic INR monitoring in patients on anticoagulants. | ODS omega-3 |
No rows in this table match the filter.
Spacing doses apart
For the gut interactions, NIH fact sheets give separation times. They range from 1 hour (zinc and penicillamine) to 6 hours (dolutegravir after calcium). The label and the pharmacist give the instruction for a specific product; these are the values the fact sheets report.
Show data: spacing as each source words it
| Medicine | Supplement | Spacing the source gives | Source |
|---|---|---|---|
| Quinolone antibiotics | Calcium | 2 h before or 2 h after calcium | ODS calcium |
| Dolutegravir | Calcium | 2 h before or 6 h after calcium | ODS calcium |
| Levothyroxine | Calcium carbonate | Not within 4 h of the supplement | ODS calcium |
| Oral bisphosphonates | Magnesium | At least 2 h apart | ODS magnesium |
| Tetracyclines or quinolones | Magnesium | At least 2 h before or 4–6 h after magnesium | ODS magnesium |
| Levothyroxine | Iron | Not within 4 h of iron (some labels) | ODS iron |
| Quinolones or tetracyclines | Zinc | At least 2 h before or 4–6 h after zinc | ODS zinc |
| Penicillamine | Zinc | At least 1 h apart | ODS zinc |
Nutrients with each other
Six documented pairs change absorption: vitamin C and meat raise nonheme iron absorption, vitamin D raises calcium absorption, iron at 25 mg or more lowers zinc absorption, zinc at 50 mg/day or more for weeks can inhibit copper absorption, and calcium might lower iron absorption. Large amounts of folate can correct the anemia of vitamin B12 deficiency but not its neurological damage.
| Nutrient or food | With | Effect | What happens | Note from the source | Source |
|---|---|---|---|---|---|
| Vitamin C | Nonheme iron (iron from plant foods) | Raises | Vitamin C improves absorption of nonheme iron.Absorption | Low vitamin C intake can decrease nonheme iron absorption. | ODS vitamin C ODS iron |
| Meat, poultry and seafood | Nonheme iron | Raises | Enhance nonheme iron absorption.Absorption | ODS iron | |
| Vitamin D | Calcium | Raises | Vitamin D promotes calcium absorption in the gut and is required for absorption by active transport.Absorption | ODS vitamin D ODS calcium | |
| Calcium | Iron (heme and nonheme) | Lowers | Calcium might reduce the bioavailability of both forms; the effect has not been definitively established.Absorption | ODS iron | |
| Iron, 25 mg or more | Zinc taken at the same time | Lowers | Can reduce zinc absorption and plasma zinc concentrations.Absorption | Iron added to enriched or fortified foods does not significantly interfere with zinc absorption. | ODS zinc |
| Zinc, 50 mg/day or more for weeks | Copper | Lowers | Can inhibit copper absorption; chronic excess can cause copper deficiency.Absorption | The adult zinc UL, 40 mg/day, is based on the adverse effect of zinc on copper status. | ODS zinc |
| Folate, large amounts | Vitamin B12 deficiency | Masks | Can correct the megaloblastic anemia of B12 deficiency but not its neurological damage.Nutrient status | ODS notes that concern has shifted to large amounts of folate precipitating or worsening the anemia and cognitive symptoms of vitamin B12 deficiency. | ODS folate |
| Vitamin E, large doses | Low vitamin K intake | Adds risk | Large doses can increase bleeding risk, especially with low vitamin K intake.Same body system | ODS vitamin E |
No rows in this table match the filter.
Plant compounds with nutrients
Phytate and some polyphenols in grains, beans and legumes lower iron and zinc absorption. The most quoted pairing, piperine with curcumin, is most often traced to a small 1998 study in which curcumin alone was mostly undetectable, so its 2000% compares against a baseline near zero.
Higher curcumin exposure also carries a documented safety risk. NCCIH says highly bioavailable formulations may harm the liver, and NIH LiverTox links such products to cases of liver injury.
| Plant compound | With | Effect | What happens | Note from the source | Source |
|---|---|---|---|---|---|
| Phytate (grains and beans) | Nonheme iron | Lowers | Phytate inhibits nonheme iron absorption.Absorption | ODS iron | |
| Phytate (legumes and whole grains) | Zinc | Lowers | Phytate binds zinc in the intestine and forms an insoluble complex that inhibits its absorption.Absorption | ODS zinc | |
| Polyphenols in some plant foods (cereals, legumes) | Nonheme iron | Lowers | Certain polyphenols inhibit nonheme iron absorption.Absorption | In a typical Western diet the effects of these enhancers and inhibitors are attenuated. | ODS iron |
| Piperine (black pepper), 20 mg | Curcumin, 2 g | Raises | In ten healthy men, serum curcumin was undetectable or very low after curcumin alone; with piperine “the increase in bioavailability was 2000%.”Absorption | The 2000% is relative to a baseline mostly below detection; it measures serum curcumin, not an effect. | Shoba 1998 |
| High-bioavailability curcumin products, some with piperine | The liver | Safety signal | Highly bioavailable curcumin formulations “may harm your liver”; LiverTox links such products to cases of liver injury.Mechanism not stated by the source | LiverTox: HLA-B*35:01 in over 70% of turmeric liver-injury cases versus 10–15% of controls. | NCCIH turmeric LiverTox turmeric |
No rows in this table match the filter.
Foods with medicines
FDA warns that grapefruit juice raises the blood levels of some medicines and lowers others, and that Seville oranges, pomelos and tangelos might act the same way. For warfarin, NIH advises a consistent vitamin K intake from food and supplements rather than sudden changes (vitamin K row above).
| Food | With | Direction | What happens | Note from the source | Source |
|---|---|---|---|---|---|
| Grapefruit juice | Some statins (simvastatin, atorvastatin), nifedipine, cyclosporine, buspirone, budesonide, amiodarone | Raises drug level | More of the drug enters the blood and stays in the body longer (intestinal enzyme CYP3A4).Metabolism or transport | FDA lists grapefruit juice as a moderate CYP3A inhibitor whose effect varies with brand, concentration, dose and preparation. | FDA grapefruit juice FDA interaction table |
| Grapefruit juice | Fexofenadine (antihistamine) | Lowers drug level | Grapefruit juice affects drug transporters, so less drug can reach the blood.Metabolism or transport | Fexofenadine may also not work as well with orange or apple juice. | FDA grapefruit juice |
| Seville oranges, pomelos, tangelos | The same medicines as grapefruit juice | May act like grapefruit | Might have the same effect as grapefruit juice.Metabolism or transport | FDA grapefruit juice |
No rows in this table match the filter.
What “synergistic” requires
Each combination above that increases a level (vitamin C or meat with nonheme iron, vitamin D with calcium, piperine with curcumin) acts on absorption. None of them was measured as synergy. In pharmacology, synergy means a combined effect larger than a named reference model predicts from each ingredient alone.
A label that calls a product “synergistic” therefore needs dose–response data for each ingredient alone and together, the model named, and confidence intervals; a claim about people needs a human trial built to test the interaction (combination science).
| Term | Meaning | Data needed |
|---|---|---|
| Pharmacokinetic enhancement | One ingredient raises the blood level of another (piperine with curcumin; vitamin C with nonheme iron) | Blood levels or absorption with and without the partner; says nothing about effect |
| Additivity (Loewe) | Each ingredient acts as a dilution of the other: dA/DA + dB/DB = 1 at a chosen effect level | Dose–response curves of each alone and of the mixture |
| Bliss independence | Ingredients act independently: expected effect EA + EB − EA·EB (effects as fractions of maximum) | Effects of each alone and together at the same doses |
| Highest single agent | Expected effect is the larger of the two single effects | Same as Bliss |
| Synergy, antagonism | Observed effect above, or below, the reference model's expectation; the Saariselkä agreement asks authors to write “Loewe synergy” or “Bliss synergy” | Replicated measurements with confidence intervals, model stated |
| Combination index (Chou–Talalay) | CI = dA/DA + dB/DB, from median-effect fits; CI < 1 synergism, CI = 1 additive, CI > 1 antagonism | Dose–effect data for each agent and the mixture; CI is reported per effect level |
| Isobologram | Plot of the dose pairs giving one effect level; the Loewe line joins the two single-agent doses | Doses of each alone, and of mixtures, that reach that effect level |
Tang J, Wennerberg K, Aittokallio T. Front Pharmacol 2015;6:181; Chou TC. Cancer Res 2010;70:440–446. DA, DB: dose of each alone that gives the chosen effect; dA, dB: their doses in the mixture that give the same effect.
The figure shows why the model must be named. It takes two ingredients that act exactly independently (Bliss) and asks what Loewe additivity calls them. At 25% effect the mixture looks antagonistic (CI 1.175), at 50% still antagonistic (1.087), and at 75% synergistic (0.939), with no interaction at all.
Report a problem
If a supplement may have caused harm, stop using it, get medical care if needed, and report it. Consumers report voluntarily; the company named on the label has a legal duty to forward serious reports it receives.
| Who | How | Requirement | Source |
|---|---|---|---|
| Consumers, caregivers and health professionals | FDA Safety Reporting Portal (“a private citizen… submitting a voluntary report”), or FDA's general line 1-888-INFO-FDA (1-888-463-6332) | Voluntary; include as much information as you can | FDA reporting page |
| Anyone, to the company | Contact information on the product label | Voluntary | FDA 101 |
| Manufacturer, packer or distributor named on the label | Report to FDA every serious adverse event report it receives (the Safety Reporting Portal can be used) | Within 15 business days; new medical information within 1 year of the first report; records kept 6 years | 21 U.S.C. 379aa-1 |
| What counts as serious | Death, a life-threatening experience, inpatient hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an event needing medical or surgical intervention to prevent one of these | 21 U.S.C. 379aa-1 | |
Where EUTECNIQ would work
EUTECNIQ would screen botanical extracts against CYP3A and transporter probes and measure mineral binding before any human study, and would call a combination synergistic only with dose–response data against a named reference model. It has no laboratory, studies or data yet.
Related pages: Supplements A–Z · How to judge a supplement · ADME, PK and PBPK · Combination science · Risk assessment
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.